AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11368133 — intervention group
Group type: COMPARATOR
Intervention: Written information (implied control)
Number of subjects: 0
Study 9083228 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 21
Study 9083228 — intervention group
Group type: COMPARATOR
Intervention: NaCl (saline)
Number of subjects: 21
Study 8259900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative progressive exercise muscle rehabilitation program (QPE) added to physical therapy (PT) program
Number of subjects: 40
Study 3554290 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 38
Study 3554290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30938078 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal control dimension of illness representation
Number of subjects: 70
Study 30938078 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline cyclical dimension of illness representation
Number of subjects: 70
Study 30938078 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depression
Number of subjects: 70
Study 29084330 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry
Number of subjects: 56
Study 29084330 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 56
Study 29084330 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular sensitivity
Number of subjects: 56
Study 29084330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intereye symmetry for microperimetry sensitivity
Number of subjects: 56
Study 29084330 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal sensitivity
Number of subjects: 56
Study 25802473 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 45
Study 25802473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 23862715 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 96
Study 23862715 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide
Number of subjects: 96
Study 23862715 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide
Number of subjects: 96
Study 23862715 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide
Number of subjects: 96
Study 21956168 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 3 months
Number of subjects: 24
Study 21956168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18684743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for up to 120 weeks
Number of subjects: 245
Study 17250578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine dentifrice gel (CHX‐DGel, Perio.Aid)
Number of subjects: 96
Study 17250578 — intervention group
Group type: COMPARATOR
Intervention: Regular dentifrice (RegD, Everclean HEMA)
Number of subjects: 96
Study 17250578 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash (CHX‐MW, Perio.Aid)
Number of subjects: 96
Study 15710852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1.0 mg/d
Number of subjects: 472
Study 15710852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 mg/d
Number of subjects: 472
Study 15710852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 15710852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1.0 mg/d vs Placebo
Number of subjects: 472
Study 15710852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 mg/d vs Placebo
Number of subjects: 472
Study 15710852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (both dosages)
Number of subjects: 472
Study 12043767 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids, vitamin D and calcium
Number of subjects: 63
Study 12043767 — intervention group
Group type: COMPARATOR
Intervention: Calcium only (Control)
Number of subjects: 63
Study 10612342 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 177
Study 10612342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 177
Study 7861490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, orally 3 times a day for 4 days)
Number of subjects: 40
Study 7861490 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (0.2 gm, orally 3 times a day for 4 days)
Number of subjects: 40
Study 7861490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine plus Allopurinol
Number of subjects: 40
Study 7861490 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control group)
Number of subjects: 40
Study 2024742 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 40
Study 2024742 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone plus Alfentanil
Number of subjects: 40
Study 2024742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 2024742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus Alfentanil
Number of subjects: 40
Study 6791203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentizol (sustained-release amitriptyline)
Number of subjects: 6
Study 6791203 — intervention group
Group type: COMPARATOR
Intervention: Ordinary amitriptyline tablets
Number of subjects: 6
Study 31698014 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% intraoral sucrose
Number of subjects: 271
Study 31698014 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 271
Study 30670228 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task aquatic exercise program, twice a week for 10 weeks, 40 minutes per session in a heated pool (33°C)
Number of subjects: 28
Study 28713116 — intervention group
Group type: EXPERIMENTAL
Intervention: LASER therapy
Number of subjects: 46
Study 28713116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise and LASER therapy
Number of subjects: 46
Study 28713116 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 46
Study 26137324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (n = 23, 0.79 ± 0.15 mEq/L)
Number of subjects: 36
Study 26137324 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (n = 13, 79.6 ± 12.4 mg/mL)
Number of subjects: 36
Study 26137324 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Lithium and Valproate
Number of subjects: 36
Study 23362326 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma miRNA profiling using reverse transcriptase quantitative PCR (RT-qPCR)
Number of subjects: 88
Study 23362326 — intervention group
Group type: COMPARATOR
Intervention: Plasma miRNA profiling
Number of subjects: 88
Study 21240457 — intervention group
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
Number of subjects: 43
Study 21240457 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin
Number of subjects: 43
Study 21240457 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel
Number of subjects: 43
Study 21240457 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 43
Study 19595444 — intervention group
Group type: EXPERIMENTAL
Intervention: Beautifil Flow F02 at 2.5 mm marginal ridge height
Number of subjects: 120
Study 19595444 — intervention group
Group type: EXPERIMENTAL
Intervention: Various restorative materials (Ketac Aplicap, Fuji IX, Fuji II LC, Beautifil Flow F02)
Number of subjects: 120
Study 19595444 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining marginal ridge height
Number of subjects: 120
Study 19595444 — intervention group
Group type: COMPARATOR
Intervention: Control group (sound teeth)
Number of subjects: 120
Study 17205445 — intervention group
Group type: EXPERIMENTAL
Intervention: E-test antibiotic strips (AB Biodisk) applied directly on respiratory tract samples
Number of subjects: 0
Study 15518296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training (n=8)
Number of subjects: 16
Study 15518296 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 16
Study 10891925 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) 0.5 mg/kg
Number of subjects: 39
Study 10891925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8808107 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 107
Study 8808107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and corticosteroids
Number of subjects: 107
Study 8808107 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and cyclophosphamide
Number of subjects: 107
Study 1364953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclo‐cryocoagulation
Number of subjects: 0
Study 1364953 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans‐scleral panretinal cryocoagulation in combination with cyclo‐cryocoagulation
Number of subjects: 0
Study 3843217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (15 to 60 mg per day)
Number of subjects: 14
Study 3843217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (dose changes)
Number of subjects: 14
Study 3492260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) high dose (50 X 10(6) IU/m2 intravenously)
Number of subjects: 114
Study 3492260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) intermediate dose (30 X 10(6) IU/m2 subcutaneously)
Number of subjects: 114
Study 3492260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) low dose (1 X 10(6) IU/m2 subcutaneously)
Number of subjects: 114
Study 3492260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) high dose
Number of subjects: 114
Study 3492260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A)
Number of subjects: 114
Study 31585766 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasound (POCUS)
Number of subjects: 469
Study 29140136 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-induced hyperhydration (SIH)
Number of subjects: 15
Study 29140136 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-induced hyperhydration (GIH)
Number of subjects: 15
Study 29140136 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt + Glycerol-induced hyperhydration (SGIH)
Number of subjects: 15
Study 26935859 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ACL reconstruction (n=62, within 10 weeks of injury)
Number of subjects: 121
Study 26935859 — intervention group
Group type: COMPARATOR
Intervention: Optional delayed ACL reconstruction (n=59; 30 with ACL reconstruction within 6-55 months)
Number of subjects: 121
Study 25549549 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 167
Study 25549549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticks
Number of subjects: 167
Study 25549549 — intervention group
Group type: EXPERIMENTAL
Intervention: Strips
Number of subjects: 167
Study 25549549 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbs
Number of subjects: 167
Study 25549549 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Dual use (DU) of cigarettes and Camel Snus
Number of subjects: 167
Study 25549549 — intervention group
Group type: COMPARATOR
Intervention: Tobacco abstinence
Number of subjects: 167
Study 23279371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 15 mL of 0.25% bupivacaine (group B)
Number of subjects: 60
Study 23279371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.25% bupivacaine and 1 μg/kg clonidine (group BC)
Number of subjects: 60
Study 23279371 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (group S)
Number of subjects: 60
Study 20122367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg per day for 10 weeks
Number of subjects: 67
Study 20122367 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 67
Study 18004687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB: NaHCO3 300 mg . kg (‐1) body mass)
Number of subjects: 9
Study 18004687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P: CaCO3 200 mg . kg (‐1) body mass)
Number of subjects: 9
Study 18004687 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 9
Study 18004687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB)
Number of subjects: 9
Study 16841201 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization for 6-8 weeks
Number of subjects: 8
Study 16841201 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloading (3-5 days after immobilization)
Number of subjects: 8
Study 16841201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (10 weeks)
Number of subjects: 8
Study 14557359 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine BOLD-MRI
Number of subjects: 25
Study 14557359 — intervention group
Group type: COMPARATOR
Intervention: Adenosine thallium SPECT
Number of subjects: 25
Study 11094666 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.125% with fentanyl 2 micrograms/ml
Number of subjects: 36
Study 11094666 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.125%
Number of subjects: 36
Study 8883031 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid, ranitidine, and misoprostol (prostaglandin E1)
Number of subjects: 87
Study 8883031 — intervention group
Group type: COMPARATOR
Intervention: Antacid and ranitidine
Number of subjects: 87
Study 8883031 — intervention group
Group type: COMPARATOR
Intervention: Antacid, ranitidine, and bismuth (De Nol)
Number of subjects: 87
Study 1383590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicord (antiarrhythmic agent)
Number of subjects: 0
Study 1383590 — intervention group
Group type: COMPARATOR
Intervention: Ethmozine (control)
Number of subjects: 0
Study 2864634 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 1884
Study 2864634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study 29715553 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline model (preoperative period)
Number of subjects: 3569
Study 29715553 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative model
Number of subjects: 3569
Study 29715553 — intervention group
Group type: EXPERIMENTAL
Intervention: At-discharge model
Number of subjects: 3569
Study 29715553 — intervention group
Group type: EXPERIMENTAL
Intervention: All models with score ≥8 points
Number of subjects: 3569
Study 30047579 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training group (FTG; n = 27, 14 women)
Number of subjects: 50
Study 30047579 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 23, 11 women)
Number of subjects: 50
Study 26895345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-IUD
Number of subjects: 703
Study 26895345 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 703
Study 24709166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 77
Study 24709166 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin plus Metronidazole
Number of subjects: 77
Study 23385630 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 60
Study 23385630 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 60
Study 23385630 — intervention group
Group type: COMPARATOR
Intervention: Pegaptanib (0.3 mg)
Number of subjects: 60
Study 21467832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group T-S)
Number of subjects: 130
Study 21467832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group T-P)
Number of subjects: 130
Study 17184783 — intervention group
Group type: COMPARATOR
Intervention: Brief advice alone
Number of subjects: 91
Study 17184783 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual nurse support
Number of subjects: 91
Study 17184783 — intervention group
Group type: EXPERIMENTAL
Intervention: Group support facilitated by nurses
Number of subjects: 91
Study 17164742 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine 1000 mg b.i.d. (n=22)
Number of subjects: 45
Study 17164742 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=23)
Number of subjects: 45
Study 12792657 — intervention group
Group type: EXPERIMENTAL
Intervention: Myristic acid meal (M)
Number of subjects: 10
Study 12792657 — intervention group
Group type: COMPARATOR
Intervention: Stearic acid meal (S)
Number of subjects: 10
Study 11148849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ovarian drilling by minilaparoscopy under local anesthesia (Group A)
Number of subjects: 62
Study 11148849 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ovarian drilling by traditional laparoscopy under general anesthesia (Group B)
Number of subjects: 62
Study 8682263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional Filter (BF) - 340 Patients
Number of subjects: 647
Study 8682263 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral Filter (SF) - 258 Patients
Number of subjects: 647
Study 8682263 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Mar Filter (DF) - 49 Patients
Number of subjects: 647
Study 8682263 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all filters
Number of subjects: 647
Study 1570975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator without an arterial line filter (n = 9)
Number of subjects: 29
Study 1570975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with a depth adsorption filter (n = 10)
Number of subjects: 29
Study 1570975 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-sheet membrane oxygenator without a filter (n = 10)
Number of subjects: 29
Study 1570975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI findings
Number of subjects: 29
Study 3898298 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg, intravenous injections, 3 times a week for 3 consecutive weeks)
Number of subjects: 41
Study 3898298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3898298 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 41
Study 31277111 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive periodontal surgery
Number of subjects: 33
Study 31277111 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 33
Study 29077992 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin‐(9‐39) at a maximum recommended starting dose of 27 mg kg‐1 day‐1 intravenously
Number of subjects: 26
Study 29077992 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 26
Study 27003305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)‐8 induced gallbladder emptying
Number of subjects: 10
Study 27003305 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10
Study 27003305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CCK and Metformin
Number of subjects: 10
Study 27003305 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-induced gallbladder emptying
Number of subjects: 10
Study 27003305 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 10
Study 23760362 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (N = 14)
Number of subjects: 19
Study 23760362 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 5)
Number of subjects: 19
Study 22287353 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 as conventional neoadjuvant chemotherapy (Group A)
Number of subjects: 93
Study 22287353 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus bevacizumab (Group B)
Number of subjects: 93
Study 22287353 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy delivered 5 days after bevacizumab treatment according to NWTV (Group C)
Number of subjects: 93
Study 20735801 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 42
Study 20735801 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 42
Study 18519778 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-18 administered as a 2-h i.v. infusion on 5 consecutive days repeated every 28 days (group A)
Number of subjects: 19
Study 18519778 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-18 administered as a 2-h i.v. infusion once a week (group B)
Number of subjects: 19
Study 15840878 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic pelvic and para-aortic lymphadenectomy
Number of subjects: 427
Study 15840878 — intervention group
Group type: COMPARATOR
Intervention: Resection of bulky nodes only (Control)
Number of subjects: 427
Study 12902099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (n = 14)
Number of subjects: 21
Study 12902099 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 21
Study 10480825 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and clinical practice audit programme for general practitioners on health promotion for elderly people
Number of subjects: 267
Study 10480825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 267
Study 7496122 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyspecific antiglobulin serum (83.2% with anti-IgG)
Number of subjects: 97
Study 7496122 — intervention group
Group type: COMPARATOR
Intervention: Tube test
Number of subjects: 97
Study 1828543 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO (84 ± 9 U/kg body weight/week)
Number of subjects: 20
Study 1828543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal rHuEPO (133 ± 7 U/kg body weight/week)
Number of subjects: 20
Study 1828543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal rHuEPO
Number of subjects: 20
Study 1828543 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were hypertensive prior to rHuEPO therapy
Number of subjects: 20
Study 7317896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (360 mg/day)
Number of subjects: 10
Study 7317896 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 10